

# Phil Skolnick

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3663004/publications.pdf>

Version: 2024-02-01

30  
papers

2,914  
citations

361413

20  
h-index

501196

28  
g-index

31  
all docs

31  
docs citations

31  
times ranked

3479  
citing authors

#	ARTICLE	IF	CITATIONS
1	Differences in fear motivated behaviors among inbred mouse strains. <i>Psychopharmacology</i> , 1993, 111, 323-331.	3.1	397
2	Glutamate and Depression. <i>Annals of the New York Academy of Sciences</i> , 2003, 1003, 250-272.	3.8	375
3	Glutamate-based antidepressants: 20 years on. <i>Trends in Pharmacological Sciences</i> , 2009, 30, 563-569.	8.7	370
4	Intra- and interstrain differences in models of "behavioral despair". <i>Pharmacology Biochemistry and Behavior</i> , 2001, 70, 187-192.	2.9	228
5	The Opioid Epidemic: Crisis and Solutions. <i>Annual Review of Pharmacology and Toxicology</i> , 2018, 58, 143-159.	9.4	225
6	Demonstration of specific "high affinity" binding sites for [3H] imipramine on human platelets. <i>Life Sciences</i> , 1980, 26, 953-959.	4.3	206
7	Antidepressant-like actions of an AMPA receptor potentiator (LY392098). <i>Neuropharmacology</i> , 2001, 40, 1028-1033.	4.1	203
8	.beta.-Carbolines: synthesis and neurochemical and pharmacological actions on brain benzodiazepine receptors. <i>Journal of Medicinal Chemistry</i> , 1982, 25, 1081-1091.	6.4	173
9	Anxiolytic: on a quest for the Holy Grail. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 611-620.	8.7	88
10	Mitigating the Effects of Nonadherence in Clinical Trials. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1151-1164.	2.0	80
11	Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1243-1253.	2.0	79
12	Re-energizing the Development of Pain Therapeutics in Light of the Opioid Epidemic. <i>Neuron</i> , 2016, 92, 294-297.	8.1	56
13	Treatment of overdose in the synthetic opioid era. , 2022, 233, 108019.		49
14	On the front lines of the opioid epidemic: Rescue by naloxone. <i>European Journal of Pharmacology</i> , 2018, 835, 147-153.	3.5	47
15	The mechanism(s) of action of the benzodiazepines. <i>Medicinal Research Reviews</i> , 1981, 1, 3-22.	10.5	46
16	Distinct Loci Mediate the Direct and Indirect Actions of the Anesthetic Etomidate at GABA <sub>A</sub> Receptors. <i>Journal of Neurochemistry</i> , 1997, 69, 1310-1313.	3.9	40
17	Fighting Fire with Fire: Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 409-415.	2.5	40
18	Countermeasures for Preventing and Treating Opioid Overdose. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 578-590.	4.7	38

#	ARTICLE	IF	CITATIONS
19	Be positive about negativesâ€“recommendations for the publication of negative (or null) results. <i>European Neuropsychopharmacology</i> , 2019, 29, 1312-1320.	0.7	28
20	Biologic Approaches to Treat Substance-Use Disorders. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 628-635.	8.7	26
21	Addiction Therapeutics: Obstacles and Opportunities. <i>Biological Psychiatry</i> , 2012, 72, 890-891.	1.3	21
22	Translational potential of naloxone and naltrexone as TLR4 antagonists. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 431-432.	8.7	20
23	Outcome Measures in Medication Trials for Substance Use Disorders. <i>Current Treatment Options in Psychiatry</i> , 2015, 2, 113-121.	1.9	17
24	Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 947-957.	2.0	14
25	Effect of NMDAR antagonists in the tetrabenazine test for antidepressants: comparison with the tail suspension test. <i>Acta Neuropsychiatrica</i> , 2015, 27, 228-234.	2.1	13
26	From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders. <i>Psychopharmacology</i> , 2017, 234, 1347-1355.	3.1	12
27	The development of glutamate-based antidepressants is taking longer than expected. <i>Drug Discovery Today</i> , 2018, 23, 1689-1692.	6.4	12
28	Pharmacokinetic Interaction between Naloxone and Naltrexone Following Intranasal Administration to Healthy Subjects. <i>Drug Metabolism and Disposition</i> , 2019, 47, 690-698.	3.3	8
29	Cannabinoid1 (CB-1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose. <i>Journal of Neural Transmission</i> , 2020, 127, 279-286.	2.8	2
30	Harry L June. <i>Neuropsychopharmacology</i> , 2014, 39, 3135-3135.	5.4	0